Clinical trial

First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer

NCT06375707

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2024-01-09

PhasePHASE2

Study timeline

Study start (actual)2024-01-09Date precision: day

Registry last updated2026-08-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Breast Cancerunresolved

Interventions

RibociclibDRUG · verified · RxNorm: ribociclib

Sponsors & collaborators

The First Affiliated Hospital with Nanjing Medical Universitylead sponsor

Fuyang Cancer Hospitalcollaborator

Affiliated Hospital of Jiangnan Universitycollaborator

Jiangyin People's Hospitalcollaborator

Weifang Yidu Central Hospitalcollaborator

Mapped research locations

NanjingJiangsu, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06375707 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.